Cart (0 Items)
Your cart is currently empty.
View ProductsIt looks like you are visiting from outside the EU. Switch to the US version to see local pricing in USD and local shipping.
Switch to US ($)
ProteoGenix is a contract research organization (CRO) specialized in antibody discovery, engineering, and early development. We support biotech companies, pharmaceutical organizations, and academic researchers in developing antibodies, from target identification to preclinical candidate selection. With operations in both Europe and the United States, we work closely with partners worldwide. For over 25 years, we have helped scientists tackle complex biological challenges and accelerate their path toward therapeutic and diagnostic innovation.
ProteoGenix was founded in 2002 near Strasbourg (France) by a visionary entrepreneur and a scientist, both of whom still lead the company today.
From the beginning, the ambition was clear: to provide reliable, flexible, and expert support for complex antibody development projects.
What started as a small, expert-driven company has grown into a trusted partner for thousands of scientists worldwide, while maintaining the same commitment to scientific rigor and collaboration.
Over the years, we have supported:
Our clients come from diverse sectors, including biotech, pharmaceutical, diagnostics, veterinary health, and academic research.
We provide integrated antibody discovery and early development services, including:
Our integrated approach ensures continuity across the workflow, reducing delays and increasing the chances of success.
In addition, we offer complementary services to support your research and development workflows:
This combination of capabilities allows us to support a wide range of applications, from early research to preclinical development, with a consistent level of quality and scientific expertise.
We collaborate with:
Each project is approached with a tailored strategy aligned with your scientific and business objectives.
When selecting a CRO for antibody development, researchers look for flexibility, expertise, and reliability.
At ProteoGenix, we offer:
Every antibody project is unique. We design customized strategies based on your target and constraints.
We specialize in challenging proteins, including membrane proteins, low-immunogenic targets, and difficult epitopes — where standard approaches often fail.
Your project is managed by a scientist who works closely with you from start to finish, ensuring clarity, responsiveness, and continuity.

We are committed to maintaining high standards of quality, reliability, and environmental responsibility across all our activities.
ProteoGenix is certified ISO 9001 for quality management and ISO 14001 for environmental management, reflecting our structured processes and continuous improvement approach.
We also benefit from the French Research Tax Credit (CIR), supporting our investment in innovation and scientific development.
ProteoGenix operates globally, with headquarters in France and a growing presence in the United States.
We are active in North Carolina and the Boston area, placing us at the heart of key biotech ecosystems.
For US-based biotech and pharma companies, this means:
If you are looking for a CRO specialized in antibody discovery and early development — especially for complex or high-risk targets — ProteoGenix can support your project at every stage.